Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.

Lee WC, Samyshkin Y, Langer J, Palmer JL

Journal of medical economics13 Aug 2012Cited by 22 (Europe PMC)

PMID22834986DOI10.3111/13696998.2012.716111PepBankPUB-22834986

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

01Computer modelIn silicoOther
In a simulation of adults with type 2 diabetes, liraglutide 1.8 mg added to metformin cost $37,234 per QALY gained versus sitagliptin.
In plain wordsIn a computer model, liraglutide 1.8 mg cost $37,234 for each extra healthy year gained compared with sitagliptin.
Peptide
Liraglutide
Outcome
Not applicableICER, liraglutide 1.8 mg versus sitagliptin
Study
n: not reported in source
IMS CORE Diabetes Model, 35-year simulation
Comparator
Sitagliptin 100 mg daily
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
1.8 mg daily · 5 yearsAs given in this study.
Measurements
ICER
37.234 $ per QALY
liraglutide 1.8 mg vs sitagliptin
Source sentences
Summary
For liraglutide 1.8 mg vs sitagliptin, the ICER was $37,234 per QALY gained
2 context sentences(design, population, supporting numbers)
Summary · context
The IMS CORE Diabetes Model (CDM), a non-product-specific, validated computer simulation model that projects the long-term outcomes related to interventions for type 2 diabetes, is used for simulation of these interventions.
Summary · context
In the model, patients were treated initially on one of the three treatment options: liraglutide 1.2 mg daily, 1.8 mg daily, or sitagliptin 100 mg daily, each used as add-on therapy to metformin for 5 years.
Report a problemFND-2283498601
02Computer modelIn silicoOther
In a simulation of adults with type 2 diabetes, liraglutide 1.2 mg added to metformin cost $25,742 per QALY gained versus sitagliptin.
In plain wordsIn a computer model, liraglutide 1.2 mg cost $25,742 for each extra healthy year gained compared with sitagliptin.
Peptide
Liraglutide
Outcome
Not applicableICER, liraglutide 1.2 mg versus sitagliptin
Study
n: not reported in source
IMS CORE Diabetes Model, 35-year simulation
Comparator
Sitagliptin 100 mg daily
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
1.2 mg daily · 5 yearsAs given in this study.
Measurements
ICER
25.742 $ per QALY
liraglutide 1.2 mg vs sitagliptin
Source sentences
Summary
while for liraglutide 1.2 mg vs sitagliptin, the ICER was $25,742 per QALY gained.
2 context sentences(design, population, supporting numbers)
Summary · context
The IMS CORE Diabetes Model (CDM), a non-product-specific, validated computer simulation model that projects the long-term outcomes related to interventions for type 2 diabetes, is used for simulation of these interventions.
Summary · context
In the model, patients were treated initially on one of the three treatment options: liraglutide 1.2 mg daily, 1.8 mg daily, or sitagliptin 100 mg daily, each used as add-on therapy to metformin for 5 years.
Report a problemFND-2283498602
03Computer modelIn silicoOther
In sensitivity analyses of the simulation, the ICERs for liraglutide versus sitagliptin stayed below US$ 50,000/QALY, except for the shortest time horizon of 10 years.
In plain wordsIn a computer model, liraglutide stayed below the common US cost threshold in all checks except the shortest 10-year view.
Peptide
Liraglutide
Outcome
Not applicableICER in sensitivity analyses
Study
n: not reported in source
IMS CORE Diabetes Model, 35-year simulation
Comparator
Sitagliptin 100 mg daily
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
1.2 mg and 1.8 mg daily · 5 yearsAs given in this study.
Measurements
ICER threshold in sensitivity analyses
< 50 US$/QALY
sensitivity analyses, except 10-year horizon
Source sentences
Summary
In all sensitivity analyses, including setting the change in HbA1c to the lower limits of the 95% confidence intervals, the ICERs remained below US$ 50,000/QALY, a commonly accepted threshold in the US, except for the shortest time horizon of 10 years.
2 context sentences(design, population, supporting numbers)
Summary · context
The IMS CORE Diabetes Model (CDM), a non-product-specific, validated computer simulation model that projects the long-term outcomes related to interventions for type 2 diabetes, is used for simulation of these interventions.
Summary · context
In the model, patients were treated initially on one of the three treatment options: liraglutide 1.2 mg daily, 1.8 mg daily, or sitagliptin 100 mg daily, each used as add-on therapy to metformin for 5 years.
Report a problemFND-2283498603

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00700817

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

Novo Nordisk A/Sn = 665Jun 2008 to Jun 2010

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 8 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.